Stoke Therapeutics Inc (STOK)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Edward M. Kaye |
| Employees: | 100 |
| Web site: | stoketherapeutics.com |
|
45 WIGGINS AVENUE, BEDFORD, MA, 01730
781-430-8200
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Stoke Therapeutics, Inc. develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy.
Please log in first to see chart